NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT® (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib. Although PFS was numerically higher in patients treated with temsirolimus, the difference was not statistically significant. Ove

NEW YORK--(BUSINESS WIRE)--New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories, including tumors of the kidney, lung and hematologic malignancies, at the Annual Meeting of the American Society of Clinical Oncology in Chicago, IL, from June 1-5. Approximately 100 abstracts featuring Pfizers cancer treatments and investigational compounds across 20 cancer types will be presented during the meeting. We are very proud

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Emerging Markets and Established Products, at the Bank of America Merrill Lynch 2012 Healthcare Conference on Thursday, May 17, 2012 at 8:00 a.m. Pacific Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the Bank of America Merrill Lynch 2012 Healthcare Conference link in Tab 2 of the I

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The Committees recommendation will be considered by the FDA in its review of the New Drug Application (NDA) for tofacitinib. The FDA has provided an anticipated Prescription Dru

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced new data presented at the 165th Annual Meeting of the American Psychiatric Association (APA) in Philadelphia on PRISTIQ® (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder (MDD) in adults,1 including a long-term relapse prevention study. These new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety profile of PRISTIQ for the tre

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline. The study, A0081242, is a Phase 3b Multicenter, Double-Blind, Randomized Withdrawal Efficacy and Safety Study of Pregabalin in the Treatment of Patients with Inadequately Tre